Last reviewed · How we verify
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
Details
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 6 |
| Start date | Wed Apr 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Apr 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Multiple Myeloma
- Plasma Cell Leukemia
Interventions
- CT0594CP
Countries
China